Protagonist Q2 net income $162.8M; ICOTYDE launch, rusfertide PDUFA in Aug 2026

Protagonist Therapeutics, Inc

Q2 2026 net income $162.8M ($2.47 basic EPS) vs net loss $34.8M in Q2 2025; revenue $213.5M from Takeda opt-out and J&J milestones.
ICOTYDE (icotrokinra) first full quarter of commercial sales; FDA approved Mar 2026; J&J partnership with up to $580M milestones and 6-10% royalties.
Rusfertide NDA under priority review for polycythemia vera; PDUFA date Aug 2026; Takeda opt-out triggered $200M payment, additional $200M and $75M upon approval.
PN-881 (oral IL-17 antagonist) Phase 2b psoriasis program planned early Q1 2027; PN-477sc (triple agonist) Phase 1 initiated.
Cash $849.5M as of June 30, 2026; potential share buyback program announcement by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.